Get to know and reach out to the experts at Profil.

Short Bio

Grit has worked as a physician in several medical fields such as surgery, general medicine and neurology in Germany and Costa Rica. She started working in clinical research in 1999 in an international Phase III study in Latin America as an Investigator for a study testing Eletriptan in patients with migraine. She worked for 12 years in early phase studies, especially in First-in-Human studies, and started working at Profil in 2013. She is a board certified medical specialist in clinical pharmacology and as Director Clinical Pharmacology she runs the specialisation program in clinical pharmacology for medical doctors at Profil.

Publications

Here are Grit's recent publications: 

•  Andersen G, Eloy R, Heise T, Gaudier M, Mégret C, Seroussi C, Chan YP, Soula O, Riddle M, DeVries JH. ADO09, a co-formulation of pramlintide and insulin A21G, lowers body weight versus insulin lispro in type 1 diabetes. DIABETES OBES METAB 2024 Oct 26. doi: 10.1111/dom.15827. 
•  Heise T, Andersen G, Pratt EJ, Leohr J, Fukuda T, Wang Q, Kazda C, Bue-Valleskey JM, Bergenstal RM. Frequency and Severity of Hypoglycemia Under Conditions of Increased Hypoglycemic Risk with Insulin Efsitora Alfa Versus Insulin Glargine Treatment in Participants with Type 2 Diabetes. Diabetes Ther. 2024 Aug 15. doi: 10.1007/s13300-024-01605-7. 
•  Chen W, Lu J, Plum-Mörschel L, Andersen G, Zijlstra E, He A, Xie T, Li L, Hao C, Gan Z, Heise T. Pharmacokinetic and pharmacodynamic bioequivalence of Gan & Lee insulin analogues aspart (rapilin®), lispro (prandilin®) and glargine (basalin®) with EU- und US-sourced reference insulins. Diabetes Obes Metab. 2023 Dec 25. doi: 10.1111/dom.15281.
•  Andersen G, Singh G, Murugesan SMN, Gogineni R, Sharma N, Panda J, Marwah A, Loganathan S, Athalye SN. Pharmacokinetic and pharmacodynamic equivalence of Biocon's biosimilar insulin N with US-licensed Humulin® N formulation in healthy subjects: Results from the RHINE-2 (Recombinant Human INsulin Equivalence-2) study. Diabetes Obes Metab. 2023 Jun 25. doi: 10.1111/dom.14994.
•  Andersen G, Eloy R, Famulla S, Heise T, Meiffren G, Seroussi C, Gaudier M, Mégret C, Chan YP, Soula O, Riddle M. A co-formulation of pramlintide and insulin A21G (ADO09) improves postprandial glucose and short-term control of mean glucose, time in range, and body weight versus insulin aspart in adults with type 1 diabetes. Diabetes Obes Metab. 2023 May 25. doi: 10.1111/dom.14972.
•  Flint A, Andersen G, Hockings P, Johansson L, Morsing A, Sundby Palle M, Vogl T, Loomba R, Plum-Mörschel L. Randomised clinical trial: semaglutide versus placebo reduced liver steatosis but not liver stiffness in subjects with non-alcoholic fatty liver disease assessed by magnetic resonance imaging. Aliment Pharmacol Ther. 2021 Nov;54(9):1150-1161. doi: 10.1111/apt.16608. Epub 2021 Sep 27. PMID: 34570916; PMCID: PMC9292692. 
• Andersen G, Meiffren G, Famulla S, Heise T, Ranson A, Seroussi C, Eloy R, Gaudier M, Charvet R, Chan Y-P, Soula O, DeVries JH. ADO09, a co-formulation of the amylin-analog pramlintide and the insulin analog A21G, lowers postprandial blood glucose versus insulin lispro in type 1 diabetes (T1D).
  DIABETES OBES METAB 2020 Dec 18. doi: 10.1111/dom.14302. Online ahead of print. 
• Bergougnan L, Andersen G, Plum-Mörschel L, Evaristi MF, Poirier B, Tardat A, Ermer M, Herbrand T, Arrubla J, Coester HV, Sansone R, Heiss C, Vitse O, Hurbin F, Boiron R, Benain X, Radzik D, Janiak P, Muslin AJ, Hovsepian L, Kirkesseli S, Deutsch P, Parkar AA. Endothelial-protective effects of a G-protein-biased sphingosine-1 phosphate receptor-1 agonist, SAR247799, in type-2 diabetes rats and a randomized placebo-controlled patient trial. Br J Clin Pharmacol 2020 Oct 30.
• Andersen G, Plum-Mörschel L, Hockings PD, Morsing A, Palle MS, Svolgaard O, Flint A.
  Clinical characteristics of a non-alcoholic fatty liver disease population across the fibrosis spectrum measured by magnetic resonance elastography: Analysis of screening data.
  Adv Ther 2020 Oct 1. doi: 10.1007/s12325-020-01503-x. Online ahead of print
• Meiffren G, Andersen G, Eloy R, Seroussi C, Mégret C, Famulla S, Chan YP, Gaudier M, Soula O, DeVries H, Heise T.
  ADO09, a Coformulation of Pramlintide (PRAM) and Insulin A21G, Improves Postprandial Glucose vs. Novolog in Type 1 Diabetes (T1D)”
  Diabetes 69 2020 June 9. (Supplement 1)
• Zijlstra E, Andersen G, Plum-Moerschel L, Rhodes M, Patton R, Bueche B, Kuo MC, Truc H, LE, Stedmann BJ, Platton, JS 
  Variability of 501 Inhaled Insulin Absorption and Action
  Diabetes 69 2020 June 9. (Supplement 1)
• Leohr J, Dellva MA, Coutant DE, LaBell E, Heise T, Andersen G, Zijlstra E, Hermanski L, Nosek L, Linnebjerg H.
  Pharmacokinetics and glucodynamics of ultra rapid lispro (URLi) versus Humalog (lispro) in patients with type 2 diabetes mellitus: A phase I randomised, crossover study.
  Clin Pharmacokinet 2020 May 29. doi: 10.1007/s40262-020-00901-2. Online ahead of print

Browse Grit's entire list of publications or Profil's recent list of publications to see our other publications.

Selected Achievements and Work Experience